First Posted : October 10, 2022
Sponsor:
Design Therapeutics
Thursday, October 13, 2022
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
ClinicalTrials.gov Identifier: NCT05573698. A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose and Multi-Dose Study of DT-216 in Adult Patients With Friedreich Ataxia. Recruitment Status : Recruiting
Subscribe to:
Posts (Atom)
